{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:07:21Z","timestamp":1793063241937,"version":"4.5.0"},"reference-count":21,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.2967\/jnumed.121.263230","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T17:25:12Z","timestamp":1641489912000},"page":"1326-1333","source":"Crossref","is-referenced-by-count":193,"title":["Targeted\n                    <b>\u03b1<\/b>\n                    -Emitter Therapy with\n                    <sup>212<\/sup>\n                    Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial"],"prefix":"10.2967","volume":"63","author":[{"given":"Ebrahim S.","family":"Delpassand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Tworowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouzbeh","family":"Esfandiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Torgue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Shafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"2022090212401058000_63.9.1326.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.09.002"},{"key":"2022090212401058000_63.9.1326.2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.186783"},{"key":"2022090212401058000_63.9.1326.3","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.3390\/ijms20123049","article-title":"Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future","volume":"20","author":"Stueven","year":"2019","journal-title":"Int J Mol Sci."},{"key":"2022090212401058000_63.9.1326.4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0056"},{"key":"2022090212401058000_63.9.1326.5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","article-title":"177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors","volume":"13","author":"Das","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"2022090212401058000_63.9.1326.6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2214\/AJR.18.19953","article-title":"Neuroendocrine tumor therapy: 177Lu-DOTATATE","volume":"211","author":"Mittra","year":"2018","journal-title":"AJR."},{"key":"2022090212401058000_63.9.1326.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2022090212401058000_63.9.1326.8","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.2174\/0929867327999200727190423","article-title":"203\/212Pb theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer","volume":"27","author":"Li","year":"2020","journal-title":"Curr Med Chem."},{"key":"2022090212401058000_63.9.1326.9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3390\/pharmaceutics13010049","article-title":"Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications","volume":"13","author":"Nelson","year":"2020","journal-title":"Pharmaceutics."},{"key":"2022090212401058000_63.9.1326.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2553"},{"key":"2022090212401058000_63.9.1326.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.087932"},{"key":"2022090212401058000_63.9.1326.12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11523-018-0550-9","article-title":"Alpha-emitters and targeted alpha therapy in oncology: from basic science to clinical investigations","volume":"13","author":"Makvandi","year":"2018","journal-title":"Target Oncol."},{"key":"2022090212401058000_63.9.1326.13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2018.0275","article-title":"Evaluating treatment effect based on duration of response for a comparative oncology study","volume":"4","author":"Huang","year":"2018","journal-title":"JAMA Oncol."},{"key":"2022090212401058000_63.9.1326.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003825"},{"key":"2022090212401058000_63.9.1326.15","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","article-title":"Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022090212401058000_63.9.1326.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.07.1754"},{"key":"2022090212401058000_63.9.1326.17","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","article-title":"Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate","volume":"43","author":"Bergsma","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022090212401058000_63.9.1326.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2893-5"},{"key":"2022090212401058000_63.9.1326.19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00259-021-05474-1","article-title":"Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity","volume":"49","author":"Kratochwil","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022090212401058000_63.9.1326.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2857-9"},{"key":"2022090212401058000_63.9.1326.21","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.263230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T15:43:52Z","timestamp":1662133432000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.263230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,1]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.2967\/jnumed.121.263230"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.263230","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,6]]}}}